Kenvue (KVUE) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Kenvue is expected to report Q2 2026 results before market open on August 6. Analysts project earnings of $0.3188 per share and revenue of $3.966 billion; the earnings call is scheduled for 8:30 a.m. ET.
• In its previous quarter, Kenvue exceeded expectations with EPS of $0.32 versus the $0.27 consensus and revenue of $3.91 billion, up 4.5% year over year.
• The stock recently traded around $19.77, while analysts maintain a consensus “Hold” rating with a $19.58 target price. Kenvue also offers an annualized dividend of $0.84 per share, representing a yield of about 4.2%.

Kenvue (NYSE:KVUE - Get Free Report) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Kenvue to announce earnings of $0.3188 per share and revenue of $3.9660 billion for the quarter. Investors can check the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 earnings per share. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Up 0.1%

NYSE:KVUE opened at $19.77 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The stock has a 50-day simple moving average of $18.52 and a 200 day simple moving average of $17.98. Kenvue has a one year low of $14.02 and a one year high of $22.35. The company has a market capitalization of $37.97 billion, a price-to-earnings ratio of 23.26, a price-to-earnings-growth ratio of 1.50 and a beta of 0.47.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be issued a $0.21 dividend. This is a boost from Kenvue's previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Wednesday, August 12th. Kenvue's dividend payout ratio is presently 97.65%.

Insider Activity at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the business's stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.59% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. boosted its position in Kenvue by 3.1% during the 4th quarter. Invesco Ltd. now owns 17,551,036 shares of the company's stock worth $302,755,000 after acquiring an additional 522,696 shares during the period. Strive Financial Group LLC acquired a new position in shares of Kenvue in the 4th quarter valued at about $127,000. Mercer Global Advisors Inc. ADV lifted its position in shares of Kenvue by 16.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 72,316 shares of the company's stock worth $1,247,000 after purchasing an additional 10,348 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Kenvue in the fourth quarter worth approximately $320,000. Finally, Mackenzie Financial Corp boosted its holdings in shares of Kenvue by 21.2% during the fourth quarter. Mackenzie Financial Corp now owns 346,787 shares of the company's stock worth $5,998,000 after purchasing an additional 60,712 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KVUE. Zacks Research downgraded shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Wall Street Zen raised Kenvue to a "buy" rating in a report on Sunday, July 12th. Citigroup dropped their price target on Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 15th. Weiss Ratings upgraded Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Finally, UBS Group upped their price objective on Kenvue from $18.00 to $20.00 and gave the stock a "neutral" rating in a research note on Thursday, July 16th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $19.58.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.